The 2006 inclusion criteria were adenocarcinoma of the prostate, PSA ≤ 10 ng/mL, PSA density <0.2 ng/mL/mL, clinical stage T1c-2, GS equal to or below 3 + 3, ≤2 positive biopsy cores, and fitness for curative treatment. This evidence concerns the gene KLK3 and prostate adenocarcinoma.